149 related articles for article (PubMed ID: 37422382)
1. PRR7 could serve as a prognostic biomarker for prostate cancer patients.
Guo Y; Yu Q; Ke M; Wang J
Asian J Surg; 2023 Nov; 46(11):5133-5135. PubMed ID: 37422382
[No Abstract] [Full Text] [Related]
2. Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer.
Dong Z; Liu Y; Scott KF; Levin L; Gaitonde K; Bracken RB; Burke B; Zhai QJ; Wang J; Oleksowicz L; Lu S
Carcinogenesis; 2010 Nov; 31(11):1948-55. PubMed ID: 20837598
[TBL] [Abstract][Full Text] [Related]
3. ZMYND10 could serve as a prognostic biomarker for patients with prostate cancer.
Wang J; Xiao Y; Li D; Zhang C
Asian J Surg; 2023 Nov; 46(11):5376-5378. PubMed ID: 37673741
[No Abstract] [Full Text] [Related]
4. CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer.
Bastos DA; Antonarakis ES
Expert Rev Mol Diagn; 2018 Feb; 18(2):155-163. PubMed ID: 29319382
[TBL] [Abstract][Full Text] [Related]
5. Pan-cancer analysis of super enhancer-induced PRR7-AS1 as a potential prognostic and immunological biomarker.
Wang R; Liu N; Li G; Liu J; Ma X; Liu X; Li J
Front Genet; 2023; 14():1160599. PubMed ID: 37091809
[No Abstract] [Full Text] [Related]
6. Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer.
Oleksowicz L; Liu Y; Bracken RB; Gaitonde K; Burke B; Succop P; Levin L; Dong Z; Lu S
Prostate; 2012 Jul; 72(10):1140-9. PubMed ID: 22127954
[TBL] [Abstract][Full Text] [Related]
7. An overview of translational prostate cancer cohorts for prognostic and predictive studies.
Tolkach Y; Kristiansen G
Histopathology; 2019 Jan; 74(1):161-170. PubMed ID: 30565297
[TBL] [Abstract][Full Text] [Related]
8. KRT72 might serves as a prognostic biomarker for patients with prostate cancer.
Wang J; Xiao Y; Yu Q; Zhang C
Asian J Surg; 2023 Nov; 46(11):5382-5384. PubMed ID: 37673738
[No Abstract] [Full Text] [Related]
9. Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review.
Lamy PJ; Allory Y; Gauchez AS; Asselain B; Beuzeboc P; de Cremoux P; Fontugne J; Georges A; Hennequin C; Lehmann-Che J; Massard C; Millet I; Murez T; Schlageter MH; Rouvière O; Kassab-Chahmi D; Rozet F; Descotes JL; Rébillard X
Eur Urol Focus; 2018 Dec; 4(6):790-803. PubMed ID: 28753865
[TBL] [Abstract][Full Text] [Related]
10. IL-8 Produced Via Bidirectional Communication Between Prostate Cancer and M2 Macrophages as a Potential Diagnostic and Prognostic Biomarker.
Fan H; Tang Z; Tian Y; Lv Q; Zeng F
Technol Cancer Res Treat; 2023; 22():15330338231177809. PubMed ID: 37226533
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-induced angiopoietin-like protein 4 as a clinical biomarker and treatment target for human prostate cancer.
Hata S; Nomura T; Iwasaki K; Sato R; Yamasaki M; Sato F; Mimata H
Oncol Rep; 2017 Jul; 38(1):120-128. PubMed ID: 28560449
[TBL] [Abstract][Full Text] [Related]
12. Tissue biomarkers for prognosis of prostate cancer: a systematic review and meta-analysis.
Zhao L; Yu N; Guo T; Hou Y; Zeng Z; Yang X; Hu P; Tang X; Wang J; Liu M
Cancer Epidemiol Biomarkers Prev; 2014 Jun; 23(6):1047-54. PubMed ID: 24636974
[TBL] [Abstract][Full Text] [Related]
13. Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer.
Izumi K; Mizokami A; Lin HP; Ho HM; Iwamoto H; Maolake A; Natsagdorj A; Kitagawa Y; Kadono Y; Miyamoto H; Huang CK; Namiki M; Lin WJ
Oncotarget; 2016 Feb; 7(7):8389-98. PubMed ID: 26701731
[TBL] [Abstract][Full Text] [Related]
14. ZNF750: A Novel Prognostic Biomarker in Metastatic Prostate Cancer.
Montanaro M; Agostini M; Anemona L; Bonanno E; Servadei F; Finazzi Agrò E; Asimakopoulos AD; Ganini C; Cipriani C; Signoretti M; Bove P; Rugolo F; Imperiali B; Melino G; Mauriello A; Scimeca M
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047491
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.
Fredsøe J; Rasmussen AKI; Thomsen AR; Mouritzen P; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Eur Urol Focus; 2018 Dec; 4(6):825-833. PubMed ID: 28753866
[TBL] [Abstract][Full Text] [Related]
16. Hoxb13, a potential prognostic biomarker for prostate cancer.
Ouhtit A; Al-Kindi MN; Kumar PR; Gupta I; Shanmuganathan S; Tamimi Y
Front Biosci (Elite Ed); 2016 Jan; 8(1):40-5. PubMed ID: 26709644
[TBL] [Abstract][Full Text] [Related]
17. Elevated XPO6 expression as a potential prognostic biomarker for prostate cancer recurrence.
Hao J; Chiang YT; Gout PW; Wang Y
Front Biosci (Schol Ed); 2016 Jan; 8(1):44-55. PubMed ID: 26709895
[TBL] [Abstract][Full Text] [Related]
18. miRNAs as biomarkers in prostate cancer.
Casanova-Salas I; Rubio-Briones J; Fernández-Serra A; López-Guerrero JA
Clin Transl Oncol; 2012 Nov; 14(11):803-11. PubMed ID: 22855165
[TBL] [Abstract][Full Text] [Related]
19. Tenascin-C is a potential cancer-associated fibroblasts marker and predicts poor prognosis in prostate cancer.
Ni WD; Yang ZT; Cui CA; Cui Y; Fang LY; Xuan YH
Biochem Biophys Res Commun; 2017 May; 486(3):607-612. PubMed ID: 28341124
[TBL] [Abstract][Full Text] [Related]
20. Tumour markers in prostate cancer II: diagnostic and prognostic cellular biomarkers.
Bjartell A; Montironi R; Berney DM; Egevad L
Acta Oncol; 2011 Jun; 50 Suppl 1():76-84. PubMed ID: 21604944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
